BOUNDLESS BIO, INC. Financing Cash Flow
BOUNDLESS BIO, INC. (BOLD) reported Financing Cash Flow of $73.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-07
- BOUNDLESS BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $24.00K, a 78.76% decline year-over-year.
- BOUNDLESS BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $0.00.
- BOUNDLESS BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $113.00K.
- BOUNDLESS BIO, INC. net cash provided by (used in) financing activities for the quarter ending 2024-09-30 was -$13.00K.
- BOUNDLESS BIO, INC. net cash provided by (used in) financing activities for fiscal 2025 was $141.00K, a 99.84% decline from fiscal 2024.
- BOUNDLESS BIO, INC. net cash provided by (used in) financing activities for fiscal 2024 was $89.82M, a 8.25% decline from fiscal 2023.
- BOUNDLESS BIO, INC. net cash provided by (used in) financing activities for fiscal 2023 was $97.90M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $73.00K 10-Q · filed 2026-08-07 | |||
| 2025-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $24.00K derived: sum of 2 quarters · filed 2026-03-09 | $141.00K 10-K · filed 2026-03-09 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $117.00K 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $117.00K 10-Q · filed 2026-08-07 | |||
| 2024-12-31 | $113.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $100.00K derived: sum of 2 quarters · filed 2026-03-09 | $90.75M derived: sum of 3 quarters · filed 2026-03-09 | $89.82M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $90.63M derived: sum of 2 quarters · filed 2025-11-05 | $89.71M 10-Q · filed 2025-11-05 | $88.33M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $90.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $89.72M 10-Q · filed 2025-08-05 | $88.34M derived: sum of 3 quarters · filed 2025-08-05 | $87.89M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | -$924.00K 10-Q · filed 2025-05-09 | -$2.31M derived: sum of 2 quarters · filed 2025-05-09 | -$2.75M derived: sum of 3 quarters · filed 2025-05-09 | $96.94M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | -$1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$1.83M derived: sum of 2 quarters · filed 2025-03-27 | $97.87M derived: sum of 3 quarters · filed 2025-03-27 | $97.90M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$447.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $99.25M derived: sum of 2 quarters · filed 2024-11-07 | $99.28M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $99.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $99.73M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $31.00K 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |